Radiofrequency Ablation for the Local Management Treatment of Hepatocellular Carcinoma: Technical Aspects and Outcomes

Alvaro Martinez-Camacho\textsuperscript{a,b}, Heather Laskey\textsuperscript{a}, Blaze Cook\textsuperscript{b}

\textsuperscript{a} University of Colorado Denver, 12631 E. 17\textsuperscript{th} Ave, MS B158, Aurora, CO 80045

\textsuperscript{b} Denver Health Hospital and Authority, 660 Bannock St, MC 4000, Denver, CO 80204

Corresponding Author:
Alvaro Martinez-Camacho, MD
Denver Health Hospital and Authority
660 Bannock St, MC 4000
Denver, CO 80204
Phone: 303-602-5032
Fax: 303-602-5055
Email: alvaro.martinez-camacho@dhha.org
Abstract:

Hepatocellular carcinoma (HCC) is the 3rd leading cause of cancer-related death worldwide, and the incidence of HCC is rising in the United States. Patients with cirrhosis of the liver and viral hepatitis are at the highest risk of developing HCC. The diagnosis of HCC can be made radiographically, with multiphase contrast-enhanced imaging; however, many lesions require biopsy for diagnosis. Various staging and treatment modalities are available for the management of confirmed HCC. Treatment can be classified as curative or palliative based on the Barcelona Clinic Liver Cancer staging system. Curative therapies include ablation, surgical resection, and orthotopic liver transplantation. Radiofrequency ablation has become an accepted first-line treatment for small tumors because of its similar outcomes and less morbidity when compared with surgical resection. However, local recurrence after radiofrequency ablation remains problematic and requires vigilant post-ablation surveillance imaging. Prior to radiofrequency ablation, the physician must take into account tumor size and location as well as ability to obtain real-time imaging for a percutaneous approach, which is preferred. The procedure requires collaboration with an experienced interventional radiologist in order to obtain the best outcomes and minimize complications. Additionally, radiofrequency ablation can also be used in combination with other treatment modalities, such as transarterial chemoembolization, to provide an adequate ablation bed for large tumors. Overall, the utilization of radiofrequency ablation should be part of the armamentarium of all physicians managing patients with HCC. This article reviews appropriate indications, technique, patient and tumor selection, advanced treatment techniques, complications, follow up, and post-treatment outcomes of radiofrequency ablation treatment of HCC.
Keywords: Radiofrequency ablation, hepatocellular carcinoma, survival, recurrence, complication

Conflict of Interest: No potential conflict of interest relevant to this article was reported by any author.
Worldwide, hepatocellular carcinoma (HCC) is the 5th and 7th most common cancer in men and women, respectively (1). Furthermore, HCC is the 3rd leading cause of cancer-related death globally, with close to 700,000 deaths recorded in 2008. In the United States, HCC is the most rapidly increasing cause of cancer-related death and indication for liver transplantation (2-4). The incidence of HCC in the United States is likely to continue rising as the “baby boomer” population with chronic hepatitis C virus infection ages, with the associated increase in risk of cirrhosis.

RISK FACTORS AND SCREENING AND DIAGNOSIS

Risk factors for HCC include cirrhosis, chronic viral hepatitis (HCV, HBV), family history of HCC, alcoholic liver disease, smoking, metabolic syndrome, chronic aflatoxin ingestion, hemochromatosis, and oral contraceptive use (5, 6). Some of these are modifiable (chronic viral hepatitis, metabolic syndrome, alcohol and tobacco behaviors), but others are not. —

Cirrhosis of the liver is the most important risk factor for HCC. Because of this close association, the major hepatology societies recommend periodic screening with contrast-enhanced imaging for HCC in cirrhotic patients (5-8). In the United States, the American Association for the Study of Liver Disease recommends biannual screening with ultrasound in patients with cirrhosis. These societal recommendations have met some resistance because screening has not been proven to reduce mortality as well as concerns for lead time bias (10, 11). However, screening of appropriate patients at risk for HCC is common practice in major hospital systems that have a hepatology service, and the increased screening likely will lead to an increase in the incidence of recognized HCC. — Contrast-enhanced imaging is the preferred method for diagnosing an HCC (5-8). The regional guidelines have notable differences which are highlighted in a recent review (5-7, 9). Our center relies on a liver protocol CT:
however, contrast-enhanced multiphase MRI or contrast-enhanced ultrasound may also be used. If HCC cannot be diagnosed on multi-phase imaging, then we perform a targeted liver biopsy. A liver biopsy is necessary. After a lesion is diagnosed as HCC, we recommend referral to a specialist in the treatment of HCC. Our center has a multi-disciplinary committee of hepatologists, surgeons, radiologists, interventional radiologists, oncologists, and palliative care medicine physicians to help coordinate and provide care to patients with HCC.

**STAGING AND TREATMENT ALGORITHMS**

Numerous staging systems for HCC are available, including TNM, Okuda score, Barcelona Clinic Liver Cancer (BCLC) system, Cancer of the Liver Italian Program (CLIP), and others (10, 11). The American Association for the Study of Liver Disease has endorsed the use of the Barcelona Clinic Liver Cancer (BCLC) staging system, which includes assessment of the patient’s performance status, Child-Pugh classification, and underlying portal hypertension (12).

The BCLC staging system is routinely used in our practice. The BCLC staging system has an advantage over other staging systems in that it links staging of HCC with a preferred treatment. Additionally, frequent inclusion of the BCLC staging system in clinical studies has provided the clinician the ability to estimate patient survival based on the stage of HCC.

Treatment for HCC can be viewed as curative or palliative based on the BCLC staging system. Curative therapy for HCC has historically included surgical resection and, more recently, radiofrequency ablation (RFA) and orthotopic liver transplantation (OLT). Palliative therapy for HCC includes transarterial chemoembolization (TACE) and systemic chemotherapy with sorafenib. Transarterial radioembolization has gained support over the last several years, but its routine use in clinical practice is limited by its high cost. A relatively new modality for the
treatment of HCC, microwave ablation, creates thermal destruction of tissue via a different mechanism than RFA that is less susceptible to the heat-sink effect (13). The role of microwave ablation in the routine treatment of HCC continues to evolve and will not be discussed in detail during this review.

Each patient discussed at our multi-disciplinary committee is evaluated using the BCLC staging system for Evaluation of a patient for potential curative therapy should always be the first step of assessment after the diagnosis of HCC. Our center relies on RFA to treat HCC that is not amenable to liver transplant or resection. The numbers of patients treated with RFA for HCC likely will increase as more clinicians screen cirrhotic patients for HCC and donor organs for OLT remain scarce. This article will review the use of RFA for the treatment of HCC, with particular emphasis on technique, appropriate selection of patients and tumor characteristics, treatment of tumors in difficult locations, post-ablation survival, and complications associated with this treatment.

**IMPORTANT CONSIDERATIONS PRIOR TO RF A TECHNIQUE**

Thermal destruction of malignant tissue with minimal collateral injury to the hepatic parenchyma is the goal of RFA. Thermal destruction is achieved via delivery of electromagnetic energy in a closed-loop circuit that includes the radiofrequency generator, a monopolar needle electrode, and a large dispersive electrode (grounding pad). A more detailed physiologic description of RFA for liver tumors has been reported (14). Advantages of percutaneous RFA over a surgical approach are shorter length of hospitalization and fewer wound complications.
Two important issues should be considered when contemplating the use of RFA administered via a percutaneous technique. First, adequate real-time visualization of the HCC is necessary in order to achieve complete ablation response as well as low rates of recurrence. Ultrasound, CT, and open MRI can be used to target the lesion during RFA (15). Our center uses real-time ultrasound imaging to identify target lesions for RFA. Ultrasound imaging can be hindered by small size of the lesion, especially in the setting of macronodular cirrhosis, and poor acoustic windows due to patient weight or tumor location (dome of the liver). The use of ultrasound contrast agents may be helpful to highlight lesions that are difficult to image, but their rapid washout from the tumor makes them of limited use intra-procedurally. The use of contrast agents for this indication has been described, but most contrast agents are not available for use in the United States (16). Additionally, contrast-enhanced ultrasound can be used immediately after RFA in order to determine the size of the ablation bed. We recommend caution using this technique as immediate post-RFA contrast-enhanced ultrasound examination frequently and significantly underestimated the size of the ablation bed compared to contrast-enhanced CT performed 24 hours later (29 mm vs. 35 mm, respectively; p<0.001) (17). Our center has used a two-stage strategy of lipiodol staining in order to improve visualization of poorly-liver lesions poorly defined by US and non-contrast CT liver lesions. The first stage involves hepatic artery angiography with transarterial delivery of lipiodol, which may also be combined with TACE as per the discretion of the treating physician. The second stage is performed shortly thereafter using non-contrast CT to identify the area of lipiodol staining for percutaneous RFA. Figure 1a illustrates a patient with a large HCC that was not considered a candidate for hepatic resection or liver transplantation. This non-contrast CT clearly highlights with lipiodol the location of the HCC which was previously not seen with US or CT. Figure 1b
shows the post-ablation appearance of the target HCC. Unfortunately, post-ablation follow-up for local recurrence after lipiodol staining is hindered by retention of lipiodol in the ablation bed. Note that the ablation bed is purposefully chosen to include a 1 cm margin around the lipiodol. Therefore, surveillance imaging must pay close attention to this non-enhancing rim to detect recurring lesions.

Another important factor to consider when contemplating the use of RFA is the ability to provide an adequate tumor ablation bed. It is widely accepted that a minimum of a 360 degree, 1 cm tumor-free margin is necessary for each ablation site. This degree of tumor-free margin is associated with a lower rate of local recurrence, as it accounts for under-sized tumor on pre-operative imaging and destruction of local microsatellite lesions. Older-generation needle electrodes and techniques could provide only an adequate tumor-free margin for lesions 2 cm and smaller. But newer electrodes, which include expandable multiple-tined designs or an overlapping ablation technique, and intra-procedural resistance monitoring, and an overlapping ablation technique, allow for treatment of larger tumors up to 5 cm (18). Though these techniques have increased the effectiveness of percutaneous RFA for larger liver lesions, they are also associated with longer, more complex procedures that require frequent repositioning of electrodes under ultrasound guidance. A novel technique of RFA using a multiple-electrode switching system was developed to overcome the need for repeated repositioning of the electrodes and still allow for large ablation beds (19). This technique is particularly unique as it allows for impedance-assisted switching of current between 3 electrodes that maintains higher inter-electrode temperatures without frequent need of repositioning thereby allowing for more thorough coagulation necrosis of target tissue. A recent mid-term analysis using this technique revealed a large mean ablation volume was achievable (~85 cm^3) as well as lower rates of local...
tumor progression after 3 years of follow-up compared to standard RFA for HCC’s smaller than 5 cm (20).

**PATIENT AND TUMOR CHARACTERISTICS TO CONSIDER BEFORE USING RFA**

Before beginning RFA treatment of HCC, multiple characteristics of the patient and tumor must be taken into account. The main patient characteristics are performance status, comorbid conditions, and liver function. Our center utilizes the Child-Pugh classification system (21) to evaluate the liver function of potential RFA candidates, but it should be noted that no single test can perfectly assess the liver function. However, patients with elevated bilirubin (>3.0 mg/dl), refractory ascites, resistant encephalopathy, or significant coagulopathy (INR > 1.5) should be approached with caution as their underlying liver disease may not tolerate the loss of liver parenchyma resulting from RFA. These same patient characteristics are considered contraindications to surgical resection. Our center typically excludes patients with Child-Pugh class C liver disease because their risk of death is higher from the underlying liver disease than from HCC if the tumor is small (<3cm). We evaluate patients with Child-Pugh class B liver disease on a case-by-case basis. Other patient factors, such as thrombocytopenia (<50 x 10^9 per liter), portal vein invasion, distant metastases, or multiple uncontrolled comorbidities should also be considered contraindications to RFA (22).

Tumor location is an important determinant in the overall feasibility of RFA (15). An HCC located near the hepatic hilum or gallbladder should be approached with caution due to the risk of thermal injury to the biliary system or gallbladder, which may result in leaks or strictures. We typically refer patients with these difficult-to-access tumors including those near the gallbladder to our surgeons for a laparoscopic approach, which can reduce the risk of thermal...
injury to adjacent structures. Advanced percutaneous techniques have been described for avoiding these structures, but they add considerable time and technical difficulty. For example, for lesions near the gallbladder fossa, the gallbladder may be displaced to prevent thermal injury by the use of 5% dextrose D5W (hydrodissection) as described by Chen et al (23). Alternatively, interposition of a balloon between the gallbladder and the lesion (physical percutaneous dissection). Another case series showed that using intra-ductal chilled saline perfusion via a nasobiliary tube during RFA of an HCC located near the hepatic hilum reduced the risk of thermal injury to the biliary tree, but we have not used this technique (24). Another location of HCC that requires caution is the subcapsular site, sometimes referred to as an exophytic lesion. Treatment with RFA of subcapsular tumors carries the risk of thermal injury to adjacent gastrointestinal organs, the abdominal wall, or diaphragm and an increased risk of intra-peritoneal bleeding or tumor seeding. However, researchers have shown that an HCC located near peritoneal organs or the diaphragm may safely be treated with percutaneous RFA by use of an artificial ascites technique (25, 26). We have used the preceding advanced techniques when treating patients who were not amenable to a surgical approach due to associated comorbid conditions. Alternatively, these tumors and those near the gallbladder may be treated via a laparoscopic approach, which can reduce the risk of thermal injury to adjacent structures, with no significant difference in survival or recurrence compared with those outcomes of percutaneous RFA (28). Finally, ablation of an HCC that is adjacent to a large hepatic vessel (≥ 3 mm) is feasible, but should be approached with caution due to the heat-sink effect. The effectiveness of RFA to destroy tissue relies on achieving high tissue temperatures to induce coagulation necrosis. If a lesion is adjacent to a large vessel, then the ability to achieve the appropriate intra-lesional temperature is diminished. Therefore, in that
situation-the post-ablation tumor response should be monitored closely because of a risk of incomplete ablation from a heat-sink effect, which is a down-side limited to RFA. We use TACE followed by RFA to treat lesions adjacent to a large vessel because the embolization should theoretically reduce the heat-sink effect thereby increasing the tissue destructive effect of RFA. Alternatively, we have found that PEI of the lesion adjacent to the vessel followed by RFA can provide an adequate ablation zone. Though not currently available in our practice, percutaneous microwave ablation is another technique that can destroy cancer tissue near a large vessel without combination therapies because it relies on a different mechanism to achieve thermal destruction of target tissues (27).

Tumor size and number are important when assessing a patient for RFA. There are no evidence-based recommendations for the limit in tumor size or number. However, the Cardiovascular and Interventional Radiological Society of Europe released guidelines in 2010 recommending that RFA be limited to a tumor size no more than 3 cm (15). The BCLC staging system closely follows the Milan criteria, which are used in the United States for the assessment of patients undergoing liver transplantation for HCC. The Milan criteria dictate that a uninodele HCC should be < 5 cm, a multinodular tumor should be < 3 cm in size, and there should be no more than three tumors (26). Furthermore, evidence of metastatic disease or portal vein invasion is considered outside of the Milan criteria. However, small (< 3 cm) single lesions are preferred for RFA. Two randomized controlled studies have demonstrated that RFA is as effective and safer than hepatic resection for HCC smaller than 3 cm (28, 29). Data regarding medium-sized lesions (3-5 cm) are mixed and controversial, with a wide range in reported technical success (61-96%) (30-32). Therefore, the use of RFA of medium-sized lesions is at the discretion and experience of the operator. Tumors greater than 5 cm frequently cannot be completely ablated by
any single technique or device; therefore, lesions larger than 5 cm should receive other treatment modalities or RFA in combination with TACE—other local therapies such as TACE (33, 34).

**COMBINATION LOCAL THERAPY WITH RFA**

Combination therapies of TACE or PEI with RFA were implemented in several small studies in order to improve the efficacy of local regional therapy. However, evidence-based criteria for use of combination therapy with RFA are not available. Our center typically relies on the use of TACE prior to RFA in the setting of large HCC (>3cm) or those lesions adjacent to large (> 3 mm) vessels. In both situations, there is a risk of incomplete ablation in a single session using RFA monotherapy. A prospective trial demonstrated that TACE prior to RFA in patients with an HCC between 3 to 5 cm was associated with a substantially lower local tumor recurrence (39% vs. 6%, p=0.012) after 3 years of follow-up when compared to RFA alone (34).

The routine use of combination therapy of TACE with RFA for small lesions ≤ 3 cm was previously assessed as well (35). However, the authors demonstrated no additional benefit in terms of overall survival or recurrence with the addition of TACE leading them to conclude that the combined procedure should not be routinely used for this subgroup of patients with small HCC (<3 cm).

A combination of PEI followed by RFA was also studied in a single-center prospective trial to evaluate for any additional benefit. The researchers showed that the combination of PEI-RFA improved overall survival and lowered the rate of recurrence significantly when compared to RFA monotherapy in the sub-analysis of patients with HCC between 3 to 5 cm (36). No significant difference in overall survival was noted for smaller lesions (≤3 cm). In our practice, PEI is used to treat lesions adjacent to other vital structures to reduce the risk of collateral thermal damage (34).
Finally, a recent study evaluated the combination of TACE-RFA compared to TACE-microwave ablation for HCC’s and found no difference in the median progression free survival (21 vs. 22 months, respectively; p=0.32) and only a non-significant trend towards improved overall survival (23.3 vs. 42.6 months; p=0.10) (37). Ultimately, sufficient data to support the routine use of combined TACE-RFA or PEI-RFA for HCC is lacking. However, the combined therapy likely has a benefit in selected patients, particularly large (>3 cm) tumors or those near large vessels.

**POST-ABLAITION FOLLOW-UP**

Contrast-enhanced imaging with CT or MRI is recommended immediately post-ablation and at 4-6 weeks after RFA in order to verify a complete technical response to therapy. Complete technical response is defined as lack of arterial enhancement in the area of previously diagnosed HCC. A peripheral rim of enhancement may be seen on the immediate follow-up image. A peripheral rim of enhancement on the immediate follow-up imaging is typically indicative of post-ablative changes (hyperemia due to inflammation) if it is relatively concentric and symmetric with a smooth inner surface (**Figure 1**). A peripheral rim of enhancement that is eccentric, asymmetric, and/or has a nodular inner surface is more suggestive of incomplete response or local recurrence of the HCC. Of course, comparison to pre-treatment imaging is critical and any suspected residual tumor should be addressed. Surveillance imaging is typically recommended at 3, 6, 9, and 12 months after the initial RFA to assess for incomplete response or local recurrence or de novo lesions (15). Thereafter, surveillance intervals may be lengthened to every 6 months (for 3 years) in patients without cirrhosis or life-long for patients with cirrhosis.

**COMPLICATIONS**
Percutaneous RFA is typically considered a low-risk procedure, but it is invasive and can be fatal. A meta-analysis that included randomized-controlled and observational studies described 11 deaths from 9,531 treated patients, giving a pooled mortality rate of 0.15% (38). The complications associated with these deaths included bile leak, peritonitis, tumor rupture with hemorrhage, colonic perforation, peritoneal hemorrhage, liver failure, and sudden death. This same meta-analysis found a major complication rate of 4.1% for RFA, where major complication was defined as an event that led to substantial morbidity, disability, increased level of care, or hospital admission or substantially lengthened hospital stay. The top ten reported major complications were tumor seeding, intra-peritoneal hemorrhage, hepatic abscess, ascites, pleural effusion requiring treatment, hepatic infarction, hepatic failure, perforation of a viscus lumen, and hemothorax.

RFA for hepatic tumors has no higher risk for adverse events than does alcohol or microwave ablation (34). Less frequently reported complications from RFA include localized skin burn at the site of the grounding pad, hypoxemia from sedation, subcapsular hematoma, cardiac tamponade, diaphragmatic hernia, pneumothorax, and bronchobiliary fistula (39–42). Finally, tumor seeding is a potential complication that is frequently feared though it is fortunately reported to occur infrequently (0.2–0.3% of cases) (43). Some centers have adopted a policy of ablation of the needle track to reduce the risk of tumor seeding.

Post-ablation syndrome, which typically includes symptoms such as fever, malaise, nausea, vomiting, and pain at the ablation site, should be discussed with each patient prior to RFA for HCC. The development of post-ablation syndrome is associated with larger ablation volumes or multiple tumors treated in a single session, however, symptoms of this syndrome can
be present in up to one third of all patients undergoing RFA (43). Treatment of the symptoms is typically supportive and the syndrome will typically abate over a period of a few days. Symptoms that persist for more than 7 days and especially if progressive, should alert the provider to more ominous complications such as infection or biliary injury.

We routinely observe patients in the hospital for 24 hours after percutaneous RFA to monitor for these complications. Periodic assessment of vital signs including temperature, new or progressive symptoms, and abdominal and chest examination are important to identify developing complications. Post-ablation imaging can also help detect complications before the patient develops symptoms.

OUTCOMES AFTER RADIOFREQUENCY ABLATION: OVERALL SURVIVAL

Most studies that have evaluated RFA treatment for HCC are retrospective cohort series, but a few small randomized controlled trials have been published. We remind the reader that the majority of HCC’s develop in patients with chronic liver disease. Therefore, survival is affected not only by the cancer but also by the degree of chronic liver disease. Furthermore, outcomes after RFA are usually compared with outcomes after hepatic resection or other ablative techniques and can include patients who receive first-line versus second-line therapy, combined therapy (e.g., in conjunction with TACE), and therapy of one versus more nodules. Therefore, comparison between studies is made difficult by the heterogeneity of the overall population. This section will highlight data from randomized controlled trials as well as results from large meta-analyses to provide insight into the utility of RFA for HCC.
Hepatic resection of a uninodular HCC is typically considered a first-line curative option for appropriately selected patients. In a large meta-analysis, 3 randomized controlled trials and 25 non-randomized studies comparing outcomes from RFA to hepatic resection, Wang et al. (44)(36) analyzed the overall survival of 11,873 patients who received either RFA (n=6,094) or hepatic resection (n=5,779). The majority of the patients had Child-Pugh class A liver disease, which would have a lower impact on overall survival than would more severe liver disease. In analysis of three randomized controlled trials (Figure 23), the authors found that, for lesions up to 5 cm diameter, RFA and hepatic resection had similar 3-year overall survival rates (74% vs. 79%, OR 0.98, 0.74-1.29; p=0.87). However, in the meta-analysis of non-randomized studies, Wang et al. (44) demonstrated that RFA had an inferior overall survival compared to hepatic resection (75% vs. 83%, OR 0.67, 0.52-0.85; p=0.0008). The meta-analysis found that the quality of evidence was very low due to heterogeneity. It is possible that patients who were not ideal surgical candidates because of baseline characteristics such as multiple large or bilobar lesions would preferentially receive RFA therapy, which would introduce a selection bias. Therefore, the authors performed a sub-analysis including only patients with tumor size less than or equal to 3 cm. In this sub-analysis, RFA and hepatic resection had similar overall survival rates at 3 years post-treatment. A similar analysis from the randomized controlled trials that included only patients with tumor size less than or equal to 3 cm found no difference in overall survival. Thus, these data suggest that RFA for hepatic lesions up to 3 cm in size in patients with well-compensated liver disease (Child-Pugh class A) has overall survival similar to that of hepatic resection. (39)(32)
Radiofrequency ablation has been compared to other forms of percutaneous ablation in smaller studies. A meta-analysis of 5 randomized controlled trials comparing RFA to percutaneous ethanol injection (PEI) included 701 patients evenly divided between the two treatments (354 RFA; 347 PEI) (45). The majority of patients studied had a single, small HCC and Child-Pugh classification A. The overall survival at 3 years was significantly higher in patients treated with RFA than in patients treated with PEI (82% vs. 70%; risk difference 0.116, 95% CI 0.06-0.17), and no major complications occurred with either treatment. A Cochrane database systematic review also documented superior overall survival (HR 1.64; 95% CI 1.31-2.07) for RFA compared to PEI with no overall difference in the rate of complications (46). Prior studies of PEI had shown its effectiveness in treating small tumors (<2 cm), but with significant reduction in effectiveness for larger tumors (47). PEI frequently requires 4-6 sessions in order to achieve complete ablation of a single lesion; thus, RFA is preferred over PEI due to better patient tolerability as well as superior overall survival outcomes as a percutaneous ablation technique for HCC.

The largest non-randomized, retrospective study comparing patients receiving RFA (n=7885) to those receiving microwave ablation therapy (n=77113) for HCC within Milan criteria found that local recurrence (5.2% vs. 10.9%, respectively) and overall survival at 3 years (82.7% vs. 77.6%, respectively) was statistically similar (48). 64% for RFA vs. 52% for microwave) at 3 years (49). That study included only patients with Child-Pugh A liver disease in order to prevent confounding of the overall survival from competing liver disease. The authors reported a complication rate of ~3% for each treatment. Two other retrospective studies similarly reported equal rates of local recurrence and overall survival when comparing the two modalities (49, 50). Ultimately, local ablation of HCC with RFA appears to be comparable to microwave
ablation in terms of rates of local recurrence and overall survival though studies directly comparing these techniques are limited in size. Microwave ablation appears to be an evolving therapy for liver lesions and will likely be used more often in the future. We have found no randomized trials that compared overall survival with RFA to that of microwave ablation or cryotherapy for the treatment of HCC.

RECURRENCE OF HCC

Recurrence of HCC is defined by evidence of arterial enhancement on contrast-enhanced imaging after RFA with a complete ablation (lack of arterial enhancement one month after therapy). Using this definition, recurrence of HCC may be due to incomplete ablation not detected on the initial follow-up image, interval growth from microsatellite disease that was previously missed, or *de novo* tumor growth in an at-risk liver with cirrhosis. Differentiation between these causes of recurrence may be difficult. In order to avoid inclusion of *de novo* tumors at a distant location, we here discuss findings where recurrence was defined as evidence of active tumor at or near the site of treatment.

In the 3 previously mentioned randomized trials comparing recurrence of HCC after RFA with that after hepatic resection, an equal rate 1 year after treatment was found (16% vs. 11%, \( p = 0.19 > 0.05 \)) (44). However, the recurrence rate for RFA became significantly higher at 3 years after treatment (43% vs. 29%; OR 1.48, 1.14-1.94) ([Figure 34](#)). Tumor recurrence in the non-randomized trials of the same meta-analysis demonstrated that RFA had a higher recurrence rate than did hepatic resection at 1 and 3 years after treatment (25% vs. 17% and 57% vs. 41%, respectively; \( p = 0.03 \) and 0.004, respectively, value <0.05 for both comparisons). A sub-analysis to control for selection bias that included only tumors less than 3cm found no significant
difference in rate of recurrence at 1- or 3 years after treatment with RFA versus hepatic resection (13% vs. 15% and 51% vs. 45%, respectively; \( p=0.48 \) and \( p=0.94 \), respectively -- value \( >0.05 \) for both comparisons) (Figure 4). Again, selection bias, where patients with higher tumor burden or poor surgical candidates received RFA, is possible. Overall, the rate of recurrence after RFA when compared to hepatic resection is difficult to discern due to significant patient and tumor heterogeneity in the reported studies. It probably can be concluded that the recurrence rate of HCC after RFA or surgical resection are not significantly different.

The meta-analysis of 5 randomized trials of RFA compared to PEI demonstrated a significantly reduced rate of local recurrence after 3 years in patients who received RFA therapy (22% vs. 7%) (45). Therefore, RFA should be considered superior to PEI because it not only can be accomplished with fewer sessions but has a lower recurrence rate. The aforementioned non-randomized study comparing RFA to microwave ablation found no significant difference in the rate of local recurrence (12% vs. 11%, respectively) at the treatment site (50). However, distant recurrence, defined by appearance of imaging evidence of HCC anywhere in the liver on follow-up imaging, was found in 65% of RFA-treated patients vs 81% microwave-treated patients after 5 years of follow up. A small randomized study comparing 48 patients who received RFA to 46 patients who received microwave ablation demonstrated a trend towards lower tumor recurrence in the RFA arm at 2 years after treatment (12% vs. 24%, respectively) (35). Firm conclusions comparing RFA and microwave ablation cannot be made because of a lack of larger randomized trials that assess overall survival and local recurrence after complete ablation.

We concede that tumor recurrence is an important consideration in the management of patients with HCC treated by RFA. The risk of tumor recurrence increases over time and likely is
affected by the size and number of the initial tumor as well as the presence of underlying cirrhosis with viral hepatitis. Nonetheless, RFA of a small, uninodular HCC has comparable rates of survival to hepatic resection with lower rates of complications and should be considered an appropriate treatment option for carefully selected patients. We recommend post-RFA imaging surveillance with contrast-enhanced multiphase CT or MRI for detection of recurrent HCC so that recurrent lesions can be diagnosed and retreated early.

**SUMMARY CONCLUSION**

Newly diagnosed HCC is an increasingly common cause of cancers and of cancer-related death worldwide. As primary care doctors adopt societal screening guidelines these cancers are being found at an early stage, which means that more patients are candidates for potentially curative therapy. Optimal management of these patients requires a multi-disciplinary approach (gastroenterologist or hepatologist; radiologist, including interventionalist; oncologist; and surgical team). Orthotopic liver transplantation may cure not only the HCC but also the underlying cirrhosis. Unfortunately, donor organs for OLT remain scarce. Despite some limitations related to local tumor recurrence, RFA is an excellent alternative to OLT for patients who are candidates for potentially curative therapy. In appropriately selected cases, overall survival and transplant-free survival after RFA is high and similar to that of patients who undergo surgical resection. An exact estimate of local recurrence is difficult to discern due to large variability in the literature. Therefore, post-RFA imaging is recommended as surveillance for tumor recurrence. Overall, Therefore, RFA should be a part of the armamentarium for physicians managing patients with HCC.
References


Pubmed Central PMCID: 2215355.
Pubmed Central PMCID: 3435864.
45. Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of


Figure 1. Pre-ablation lipiodol staining for difficult to visualize liver lesions. **a,** Non-contrast CT performed after hepatic artery angiography with lipiodol staining of a previously nonvisualized HCC. Note how the lipiodol provides excellent contrast resolution between the HCC and the background liver parenchyma. Percutaneous CT-guided RFA was then easily performed. **b,** Contrast-enhanced CT post-ablation demonstrates retention of the lipiodol within the target HCC. Now it is surrounded by a 1 cm margin of non-enhancing tissue that represents the tumor ablation bed.
**Figure 12.** MR and CT imaging of an HCC pre-, intra-, and post-procedurally. 

a. Contrast-enhanced MRI shows evidence of an enhancing HCC in the right hepatic lobe. 

b. Intra-procedural CT showing needle placement within the previously noted HCC. 

c. Contrast-enhanced CT/MRI immediately performed within 2 days after RFA showing lack of arterial enhancement of the treated lesion. **Note the thin, symmetric and concentric rim of enhancement characteristic of post-ablation hyperemia.** 

d. Contrast-enhanced MRI/CT four 4 weeks after RFA showing lack of enhancement of the previously documented HCC. **Note the thin, symmetric and concentric rim of enhancement characteristic of post-ablation hyperemia.** 

HCC, hepatocellular carcinoma; RFA, radiofrequency ablation.
Figure 23. Comparison of 3-year overall survival of lesions up to 5 cm. A meta-analysis of 3 RCT’s demonstrated statistically equivalent overall survival for RFA compared to surgical resection of HCC (44). RFA was inferior to surgical resection in overall survival in the meta-analysis of 25 non-randomized trials, but the studies were considered of low quality due to heterogeneity (44). RCT, randomized controlled trial; RFA, radiofrequency ablation; HCC, hepatocellular carcinoma. \( p \)-value <0.05.
Figure 34. The rate of tumor recurrence at 1 and 3 years. Recurrence of HCC at 1 year after treatment was equivalent for RFA when compared to surgical resection in the meta-analysis of 3 RCT’s (44). At 3 years, however, there was an increase in local recurrence after RFA compared to surgical resection. The meta-analysis of 25 non-randomized studies demonstrated an increased rate of recurrence of HCC at both 1 and 3 years for RFA compared to surgical resection (44).

HCC, hepatocellular carcinoma; RCT, randomized controlled trial; RFA, radiofrequency ablation; *, p value <0.05.
Sub-analysis of tumor recurrence in lesions <3cm. To control for any selection bias, a sub-analysis of the 25 non-randomized trials to compare the rate of recurrence between RFA and surgical resection including HCC’s up to 3cm in size was performed (44). The sub-analysis demonstrated an equivalent rate of recurrence at 1 and 3 years between the treatment modalities suggesting that selection bias could play a role in the results shown in figure 3. RFA, radiofrequency ablation; HCC, hepatocellular carcinoma.